Table 4 Empirical and documented therapies in bacteraemic and non-bacteraemic patients
Anti-infective regimens | Bacteraemic patients (n = 64) | Patients without bacteraemia (n = 279) | p value |
|---|---|---|---|
Empirical therapy | |||
 Combination of EAT, n (%) | 49 (77) | 226 (81) | 0.42 |
 Imipenem/cilastatin, n (%) | 22 (34) | 69 (25) | 0.12 |
 Piperacillin tazobactam, n (%) | 36 (56) | 173 (62) | 0.39 |
 Vancomycin, n (%) | 30 (47) | 122 (44) | 0.65 |
 Aminoglycosides, n (%) | 31 (48) | 140 (50) | 0.80 |
 Antifungals, n (%) | 21 (33) | 101 (36) | 0.61 |
 Fluconazole, n (%) | 17 (27) | 89 (32) | 0.45 |
 Caspofungin, n (%) | 3 (5) | 8 (3) | 0.43 |
 Adequacy of EAT, n (%) | 43 (67) | 190 (68) | 0.89 |
Documented therapy | |||
 Antibiotic treatment de-escalation, n (%) | 37 (58) | 163 (58) | 0.93 |
 Antibiotic treatment escalation, n (%) | 15 (23) | 72 (26) | 0.69 |
 Combination of EAT, n (%) | 38 (59) | 190 (68) | 0.19 |
 Imipenem/cilastatin, n (%) | 23 (36) | 56 (20) | 0.007 |
 Piperacillin tazobactam, n (%) | 20 (31) | 98 (35) | 0.55 |
 Vancomycin, n (%) | 16 (25) | 90 (32) | 0.25 |
 Aminoglycosides, n (%) | 12 (19) | 36 (13) | 0.22 |
 Antifungals, n (%) | 20 (31) | 117 (42) | 0.11 |
  Fluconazole, n (%) | 16 (25) | 104 (37) | 0.06 |
  Caspofungin, n (%) | 2 (3) | 7 (3) | 0.78 |
Duration of antibiotic therapy in daysa, median (IQR) | 10 (8–14) | 10 (8–14) | 0.89 |